Market research
DXCM DexCom Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 30B
- P/E ratio
- 31.2
- Analyst target
- 96.1923
- Dividend yield
- Not available
- Beta
- 1.48
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 30B
- P/E ratio
- 31.2
- Analyst target
- 96.1923
- Dividend yield
- Not available
- Beta
- 1.48
About
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Research context
DexCom Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the DXCM discussion.
5 years, 6 months ago
DexCom, Inc is currently in a long term uptrend where the price is trading 19.7% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.6.
DexCom, Inc's total revenue rose by 22.9% to $569M since the same quarter in the previous year.
Its net income has increased by 283.2% to $355M since the same quarter in the previous year.
Finally, its free cash flow grew by 12.2% to $112M since the same quarter in the previous year.
Based on the above factors, DexCom, Inc gets an overall score of 5/5.